Please login to the form below

Not currently logged in
Email:
Password:

migalastat

This page shows the latest migalastat news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs from Biogen and Amicus win UK Prix Galien

Orphan drugs from Biogen and Amicus win UK Prix Galien

Galafold (migalastat) is an oral medication for the treatment of Fabry disease, a rare lysosomal metabolic storage condition.

Latest news

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Acquisition of remaining rights. 1034. Scioderm. Amicus. Galafold [migalastat] for Fabry's disease.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Firstly, GSK decided to return rights to the experimental Fabry disease drug migalastat, noting that support would continue through GSK's equity investment of $3m. It was just under a year

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...
Digital therapeutics and their impact on society
Head of Customer Experience Elisa del Galdo explores how healthcare technology can help chronic disease patients and asks what makes a good digital therapeutic?...

Infographics